Phio Pharmaceuticals (NASDAQ:PHIO) Posts Earnings Results, Hits Estimates

by · The Cerbat Gem

Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.36) EPS for the quarter, hitting analysts’ consensus estimates of ($0.36), FiscalAI reports.

Phio Pharmaceuticals Stock Down 8.0%

Phio Pharmaceuticals stock traded down $0.07 during mid-day trading on Thursday, reaching $0.80. The company had a trading volume of 115,968 shares, compared to its average volume of 63,541. The firm has a market cap of $9.30 million, a price-to-earnings ratio of -0.62 and a beta of 0.93. The company has a 50 day moving average of $0.98 and a 200-day moving average of $1.08. Phio Pharmaceuticals has a 52 week low of $0.80 and a 52 week high of $1.88.

Analyst Ratings Changes

PHIO has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating on shares of Phio Pharmaceuticals in a research note on Wednesday, August 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research report on Thursday, October 15th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $14.00.

Read Our Latest Stock Analysis on Phio Pharmaceuticals

Phio Pharmaceuticals Company Profile

(Get Free Report)

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company focused on developing cancer immunotherapies. The company’s programs are designed to enhance the immune system’s ability to recognize and destroy tumor cells, with an emphasis on treatments that may be administered directly to the tumor or used in combination with other therapies.

Phio’s research is based on its INTASYL self-delivering RNA interference (RNAi) technology. The platform is intended to selectively silence genes involved in immune suppression and cancer progression without requiring a separate delivery vehicle.

Further Reading